Compass shares crash as ‘confounding’ survival data raise approvability questions for bispecific

Confounding OS Data Raises FDA Questions for Compass' Tovecimig

Compass Therapeutics' bispecific drug, tovecimig, met its primary endpoint of progression-free survival (PFS) in the Phase 2/3 COMPANION-002 study for biliary tract cancer, showing 4.7 months PFS compared to 2.6 months for the control arm, a 56% reduction in progression risk. However, the drug failed to achieve the secondary endpoint of overall survival (OS), which the company attributed to a high crossover rate (54%) from the control arm, leading to "notably prolonged survival" in those patients. This "confounding" OS data has raised significant questions about the therapy's approvability with the FDA, causing Compass shares to plummet over 63%. The company plans to discuss the data with the FDA in a pre-BLA meeting mid-year, seeking full approval.

• Positive Progression-Free Survival Outcome: Tovecimig successfully achieved its primary endpoint in the COMPANION-002 study, demonstrating a statistically significant improvement in progression-free survival. Patients treated with tovecimig plus paclitaxel experienced a median PFS of 4.7 months, a substantial increase compared to 2.6 months for the control arm, representing a 56% reduction in the risk of disease progression. This outcome underscores the drug's efficacy in slowing disease advancement in this challenging patient population.
• Confounding Overall Survival Data: Despite the PFS success, tovecimig did not meet the secondary endpoint of overall survival. This was primarily attributed to a high crossover rate, with 54% of patients from the control arm subsequently receiving tovecimig. These crossover patients exhibited an unexpectedly long survival of 12.8 months, which complicated the OS analysis and made the pooled OS data (8.9 months) statistically insignificant. This "confounding" factor is expected to be a major point of discussion with the FDA.
• Market Reaction and Regulatory Uncertainty: The mixed trial results, particularly the failure to improve overall survival, led to a sharp decline in Compass Therapeutics' stock, which fell over 63% to $1.81 per share. Analysts expressed concerns about the FDA's potential stance on approvability, given the importance of OS in oncology. Compass plans to engage with the FDA in a pre-biologics license application meeting mid-year, aiming to secure full approval for tovecimig despite the OS challenges.

COMPANION-002: Unpacking Tovecimig's Mixed Efficacy in Biliary Tract Cancer

The clinical trial landscape for biliary tract cancer encompasses diverse study designs ranging from single-arm phase 2 studies to large-scale phase 3 randomized controlled trials. Most trials employ randomized controlled designs with stratification factors including tumor location (intrahepatic vs. extrahepatic cholangiocarcinoma vs. gallbladder cancer), disease status (initially unresectable vs. recurrent), and patient characteristics such as age and performance status. Key inclusion criteria consistently require ECOG performance status 0-2, adequate organ function, and measurable disease per RECIST version 1.1. Recent trials such as PROOF 301 and TOPAZ-1 demonstrate the field's evolution toward biomarker-driven enrollment, with PROOF 301 specifically targeting FGFR2-rearranged cholangiocarcinoma and various studies focusing on HER2-positive, BRAF-mutated, or ERBB2/3-altered populations.

Primary endpoints vary substantially based on study objectives, with progression-free survival predominating in phase 2 trials and overall survival serving as the primary endpoint in definitive phase 3 studies. The TOPAZ-1 and KEYNOTE-966 trials established immunotherapy combinations as standard of care, while specialized endpoints such as R0 resection rates in conversion therapy studies (ZSAB-TransGOLP) and disease control rates in biomarker-selected populations (TAPUR basket trial) reflect the diverse therapeutic strategies under investigation. Recent meta-analyses have employed restricted mean survival time analysis to provide more nuanced survival comparisons, revealing modest but consistent benefits of approximately 1.2 months with immunotherapy combinations.

Study execution challenges are evident across multiple trials, with poor accrual leading to early termination of the PROOF 301 study despite activation at 120 sites globally. Sample sizes range from small single-arm studies (19 patients in the cabozantinib study) to large phase 3 trials (685 participants in TOPAZ-1), with most phase 2 studies enrolling 30-60 patients using Simon's two-stage design. Safety monitoring employs standardized NCI CTCAE criteria, while quality of life assessments increasingly utilize validated instruments such as EORTC QLQ-C30 and QLQ-BIL21. The integration of correlative biomarker studies and patient-reported outcomes reflects the maturation of biliary tract cancer clinical research toward precision medicine approaches and comprehensive patient-centered care evaluation.

Navigating Tovecimig's Regulatory Path Amidst OS Uncertainty

Investigational therapies for biliary tract cancer (BTC) demonstrate varying degrees of efficacy compared to established standard-of-care treatments, with some showing promising signals while others reveal limited activity. Recent investigational approaches include targeted therapies such as pemigatinib, an FGFR inhibitor that achieved a 37.0% objective response rate in previously treated advanced cholangiocarcinoma patients with FGFR2 alterations, with median progression-free survival of 7.0 months and overall survival of 17.5 months. Combination strategies like lenvatinib plus pembrolizumab showed modest antitumor activity with a 17.6% objective response rate in previously treated advanced BTC, though with manageable toxicity profiles. Photodynamic therapy (PDT) represents another investigational approach that has shown particularly encouraging results, with one prospective randomized controlled study stopped prematurely due to impressive survival improvements that made continued randomization unethical.

Standard-of-care treatments remain the foundation of BTC management, with surgical resection offering the only curative option and 5-year survival potential, though less than 20% of patients are surgical candidates at diagnosis. For advanced disease, gemcitabine with cisplatin represents the established standard of care, demonstrating superior survival and quality of life compared to best supportive care in randomized controlled trials. Adjuvant radiotherapy has shown significant overall survival benefits for extrahepatic cholangiocarcinoma with a hazard ratio of 0.62, while maintaining low late radiation-induced toxicity rates of 2-9%. However, all patients ultimately progress on gemcitabine-cisplatin therapy, highlighting the critical need for effective investigational alternatives.

The comparative effectiveness data suggests that while investigational therapies offer hope for specific patient populations, particularly those with targetable molecular alterations, they have not yet surpassed standard-of-care treatments in broad patient populations. Neoadjuvant therapy strategies show promise with improved R0 resection rates and median overall survival of 38 months versus 26 months with upfront resection. However, some investigational combinations like DKN-01 with gemcitabine/cisplatin and UFT with doxorubicin have demonstrated limited additional activity beyond historical controls, emphasizing the challenging nature of this disease and the need for continued research into novel therapeutic approaches.

Addressing Unmet Needs in Advanced Biliary Tract Cancer

Current treatment approaches for biliary tract cancer face significant obstacles that limit therapeutic efficacy and patient outcomes. The disease's aggressive nature, combined with late-stage diagnosis and inherent treatment resistance, creates substantial barriers to effective management. These challenges span from diagnostic timing to drug resistance mechanisms, highlighting the urgent need for novel therapeutic strategies.

• Late-stage diagnosis limits treatment options - Most patients are diagnosed at advanced stages when surgical resection is no longer feasible, with cholangiocarcinomas frequently presenting as unresectable disease associated with poor clinical outcomes and survival rates

• Standard chemotherapy regimens demonstrate limited efficacy - The traditional gemcitabine plus cisplatin regimen shows restricted effectiveness, while conventional chemotherapy offers only negligible survival advantages for patients with advanced disease

• Multidrug resistance significantly impairs treatment outcomes - Drug resistance poses a major obstacle to effective therapy, with multifaceted resistance mechanisms that are not completely understood, leading to high postoperative recurrence rates and low long-term survival

• Targeted therapies benefit only limited patient populations - Current targeted medicines provide clinical benefit for only a small subset of patients with specific genetic modifications, limiting their overall therapeutic impact

• Disease heterogeneity complicates treatment standardization - Biliary tract cancer exhibits high heterogeneity characterized by strong invasiveness and poor prognosis, making uniform treatment approaches challenging

• Non-coding RNA dysregulation drives therapeutic resistance - Abnormal expression of microRNAs, long non-coding RNAs, and circular RNAs contributes to resistance against different cancer therapies by rewiring signaling pathways that affect drug uptake, apoptosis, immune cell interactions, and cancer stemness

Tovecimig's Biliary Cancer Data: A PFS Victory, OS Conundrum

The landscape of biliary tract cancer (BTC) treatment is notoriously challenging, marked by aggressive disease progression and a dire prognosis, particularly for patients who have exhausted first-line therapies. In this context, the recent announcement regarding tovecimig (CTX-009) from Compass Therapeutics presents a complex picture of both promise and significant hurdles. The drug successfully met its primary endpoint, demonstrating a statistically and clinically meaningful improvement in progression-free survival (PFS) for second-line advanced BTC patients. A median PFS of 4.7 months compared to 2.6 months in the control arm, representing a 56% reduction in the risk of progression, is a notable achievement for a novel bispecific antibody targeting both DLL4 and VEGF-A, a mechanism designed to powerfully inhibit tumor angiogenesis.

However, the journey to market is rarely straightforward, and tovecimig's path has encountered a substantial obstacle: the failure to achieve its secondary endpoint of overall survival (OS). While the company attributes this to a high 54% crossover rate from the control arm, which allowed patients to receive the investigational drug and potentially confounded the OS data, this explanation introduces a critical regulatory challenge. The FDA often considers OS the gold standard for oncology approvals, and demonstrating a clear survival advantage is paramount for full approval. The explicit allowance for crossover in the trial design, while ethically sound, complicates the interpretation of the true long-term survival benefit.

This situation creates a strategic imperative for Compass Therapeutics. They must meticulously present their case to the FDA, leveraging the robust PFS data and a compelling argument that the crossover effect masked a genuine OS benefit. The market's immediate reaction, with a sharp decline in share value, underscores the investor community's sensitivity to OS data and the perceived risk to approvability. Moving forward, the company's ability to navigate these regulatory discussions and articulate a clear path to approval will be crucial. Success would not only validate a novel therapeutic mechanism but also offer a much-needed option for patients with limited hope, potentially reshaping the treatment paradigm for advanced BTC. Failure, however, would highlight the enduring challenge of bringing innovative therapies to market when definitive survival endpoints are not unequivocally met.